Abstract

Multiplexed biological assays provide multiple measurements of cellular parameters in the same test. In this work, we have trained and tested an Artificial Neural Network (ANN) model for the first time, in order to perform a multiplexing prediction of drugs effect on macrophage populations. In so doing, we have used the TOPS-MODE approach to calculate drug molecular descriptors and the software STATISTICA to seek different ANN models such as: Linear Neural Network (LNN), Radial Basis Function (RBF), Probabilistic Neural Networks (PNN) and Multi-Layer Perceptrons (MLP). The best model found was the LNN, which correctly classified 8258 out of 9000 (Accuracy=93.0%) multiplexing assay endpoints of 7903 drugs (including both training and test series). Each endpoint corresponds to one out of 1418 assays, 36 molecular or cellular targets, 46 standard type measures, in two possible organisms (human and mouse). Secondly, we have determined experimentally, for the first time, the values of EC50=11.41μg/mL and Cytotoxicity=27.1% for the drug G1 over Balb/C mouse spleen macrophages using flow cytometry. In addition, we have used the LNN model to predict the G1 activity in 1265 multiplexing assays not measured experimentally (including 152 cytotoxicity assay endpoints). Both experimental and theoretical results point out a low macrophage cytotoxicity of G1. This work breaks new ground for the ‘in silico’ multiplexing screening of large libraries of compounds. The results obtained are very significant because they complement the immunotoxicology studies of this important anti-microbial/anti-parasite drug.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.